3 transcripts
CHRS
Earnings call transcript
NASDAQ
2024 Q2
8 Aug 24
the LOQTORZI-eligible indications include 3 patient segments. First, those with recurrent locally advanced disease. Majority of NPC patients are diagnosed
CHRS
Earnings call transcript
NASDAQ
2024 Q1
9 May 24
to plan, with impressive data consistently presented at major medical conferences and more to come. Across every key dimension, the company is executing
CHRS
Earnings call transcript
NASDAQ
2023 Q4
13 Mar 24
and regulatory teams for their success in securing 3 product approvals in 2023 from the FDA. This is a major accomplishment for any company, especially one
- Prev
- 1
- Next